PCI Biotech Holding ASA (PCIB.OL)
NOK 1.33
(-0.38%)
NOK 1.33
(-0.38%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - NOK | -100.0% |
| 2022 | 327 Thousand NOK | -74.39% |
| 2021 | 1.27 Million NOK | 0.0% |
| 2020 | - NOK | -100.0% |
| 2019 | 539 Thousand NOK | 0.0% |
| 2018 | - NOK | 0.0% |
| 2017 | - NOK | 0.0% |
| 2016 | - NOK | 0.0% |
| 2015 | - NOK | 0.0% |
| 2014 | - NOK | 0.0% |
| 2013 | - NOK | 0.0% |
| 2012 | - NOK | -100.0% |
| 2011 | 1.8 Million NOK | -28.14% |
| 2010 | 2.51 Million NOK | 0.0% |
| 2009 | - NOK | 0.0% |
| 2008 | - NOK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - NOK | 0.0% |
| 2024 Q1 | - NOK | 0.0% |
| 2023 Q1 | 288 Thousand NOK | -11.93% |
| 2023 Q3 | - NOK | -100.0% |
| 2023 Q2 | 245 Thousand NOK | -14.93% |
| 2023 FY | - NOK | -100.0% |
| 2023 Q4 | - NOK | 0.0% |
| 2022 Q2 | 962 Thousand NOK | -14.03% |
| 2022 Q4 | 327 Thousand NOK | -59.38% |
| 2022 Q3 | 805 Thousand NOK | -16.32% |
| 2022 Q1 | 1.11 Million NOK | -12.37% |
| 2022 FY | 327 Thousand NOK | -74.39% |
| 2021 Q2 | 1.54 Million NOK | 0.0% |
| 2021 Q1 | - NOK | 0.0% |
| 2021 Q4 | 1.27 Million NOK | -7.86% |
| 2021 Q3 | 1.38 Million NOK | -10.06% |
| 2021 FY | 1.27 Million NOK | 0.0% |
| 2020 Q4 | - NOK | -100.0% |
| 2020 Q1 | 380 Thousand NOK | -29.5% |
| 2020 Q2 | 232 Thousand NOK | -38.95% |
| 2020 Q3 | 84 Thousand NOK | -63.79% |
| 2020 FY | - NOK | -100.0% |
| 2019 Q1 | 1.16 Million NOK | 0.0% |
| 2019 Q2 | 1.17 Million NOK | 0.77% |
| 2019 Q3 | 857 Thousand NOK | -27.25% |
| 2019 Q4 | 539 Thousand NOK | -37.11% |
| 2019 FY | 539 Thousand NOK | 0.0% |
| 2018 Q2 | - NOK | 0.0% |
| 2018 Q1 | - NOK | 0.0% |
| 2018 Q4 | - NOK | 0.0% |
| 2018 FY | - NOK | 0.0% |
| 2018 Q3 | - NOK | 0.0% |
| 2017 Q3 | - NOK | 0.0% |
| 2017 Q2 | - NOK | 0.0% |
| 2017 Q1 | - NOK | 0.0% |
| 2017 FY | - NOK | 0.0% |
| 2017 Q4 | - NOK | 0.0% |
| 2016 Q2 | - NOK | 0.0% |
| 2016 Q1 | - NOK | 0.0% |
| 2016 Q3 | - NOK | 0.0% |
| 2016 Q4 | - NOK | 0.0% |
| 2016 FY | - NOK | 0.0% |
| 2015 Q1 | - NOK | 0.0% |
| 2015 FY | - NOK | 0.0% |
| 2015 Q3 | - NOK | 0.0% |
| 2015 Q2 | - NOK | 0.0% |
| 2015 Q4 | - NOK | 0.0% |
| 2014 FY | - NOK | 0.0% |
| 2014 Q4 | - NOK | 0.0% |
| 2014 Q2 | - NOK | 0.0% |
| 2014 Q3 | - NOK | 0.0% |
| 2014 Q1 | - NOK | 0.0% |
| 2013 Q2 | - NOK | 0.0% |
| 2013 Q3 | - NOK | 0.0% |
| 2013 Q4 | - NOK | 0.0% |
| 2013 FY | - NOK | 0.0% |
| 2013 Q1 | - NOK | 0.0% |
| 2012 Q1 | - NOK | -100.0% |
| 2012 Q2 | - NOK | 0.0% |
| 2012 FY | - NOK | -100.0% |
| 2012 Q3 | - NOK | 0.0% |
| 2012 Q4 | - NOK | 0.0% |
| 2011 FY | 1.8 Million NOK | -28.14% |
| 2011 Q1 | - NOK | -100.0% |
| 2011 Q3 | - NOK | 0.0% |
| 2011 Q2 | - NOK | 0.0% |
| 2011 Q4 | 1.8 Million NOK | 0.0% |
| 2010 Q3 | - NOK | 0.0% |
| 2010 Q2 | - NOK | 0.0% |
| 2010 FY | 2.51 Million NOK | 0.0% |
| 2010 Q4 | 2.51 Million NOK | 0.0% |
| 2009 FY | - NOK | 0.0% |
| 2009 Q4 | 139 Thousand NOK | 0.0% |
| 2008 FY | - NOK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Arctic Bioscience AS | 2.04 Million NOK | 100.0% |
| Aqua Bio Technology ASA | - NOK | NaN% |
| ArcticZymes Technologies ASA | 8.41 Million NOK | 100.0% |
| BerGenBio ASA | - NOK | NaN% |
| Hofseth BioCare ASA | 97.1 Million NOK | 100.0% |
| Thor Medical ASA | - NOK | NaN% |
| Ultimovacs ASA | 1.88 Million NOK | 100.0% |